Interferon-A Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Scientists found that a combination of interferon alpha and anti-PD-1-based immunotherapy resulted in enhanced antitumor activity in unresectable hepatocellular carcinoma patients.